A Decade of Bulevirtide Use in Chronic Hepatitis Delta: Real-World Clinical Results
Journal of Gastrointestinal and Liver Diseases · 2025
DOI: 10.15403/jgld-6501 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, 2025. Verfasst von Sophia Rusch und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg…. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis D, Chronic, Hepatitis Delta Virus, Peptide Fragments. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Aims: Until recently, the only available treatment option for hepatitis D virus (HDV) was the off-label use of interferon, which is associated with limited efficacy and considerable side effects. The approval of the first HDV-direct antiviral, bulevirtide (BLV), has introduced a targeted therapeutic option for patients with chronic hepatitis delta. We assessed the clinical efficacy of BLV in our HDV patients.
Methods
We conducted a retrospective analysis of all patients diagnosed with HDV infection in our department over the past 10 years. For statistical analysis, we performed multivariate analysis of variance, MANOVA.
Results
26 patients tested positive for HDV antibodies (17 developed chronic hepatitis delta). Eleven patients received BVD. At treatment initiation, liver cirrhosis was present in three patients in the bulevirtide group (MELD-Na: 9–10; Child-Pugh: 5–7) and in three patients in the no bulevirtide group (MELD-Na: 13–18; Child-Pugh: 5–8). Over 12 months of follow-up, bulevirtide recipients showed reductions in alanine aminotransferase (ALT; mean baseline 88 U/L vs 59 U/L; controls 230 U/L vs 206 U/L; MANOVA between-subject effect: p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany. sophia.rusch@ukr.de.
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany. diana.stoeckert@googlemail.com.
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany. stephan.schmid@ukr.de.
- Department of Emergency and Intensive Care Medicine, Klinikum Stuttgart, Stuttgart, Germany. T.Schilling@klinikum-stuttgart.de.
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany. martina.mueller-schilling@ukr.de.
Zitieren
APA
Rusch, S., Stöckert, P., Schmid, S., Schilling, T., & Müller, M. (2025). A Decade of Bulevirtide Use in Chronic Hepatitis Delta: Real-World Clinical Results. Journal of Gastrointestinal and Liver Diseases. https://doi.org/10.15403/jgld-6501
Vancouver
Rusch S, Stöckert P, Schmid S, Schilling T, Müller M. A Decade of Bulevirtide Use in Chronic Hepatitis Delta: Real-World Clinical Results. Journal of Gastrointestinal and Liver Diseases. 2025. doi:10.15403/jgld-6501
BibTeX
@article{Rusch2025,
author = {Rusch, Sophia and Stöckert, Petra and Schmid, Stephan and Schilling, Tobias and Müller, Martina},
title = {A Decade of Bulevirtide Use in Chronic Hepatitis Delta: Real-World Clinical Results},
journal = {Journal of Gastrointestinal and Liver Diseases},
year = {2025},
doi = {10.15403/jgld-6501}
}
EUVIMED